mFOLFIRINOX may have a limited role in pancreatic cancer in Phase II/III trial
1. In patients with metastatic pancreatic cancer, neither modified fluorouracil, leucovorin, irinotecan and oxaliplatin (mFOLFIRINOX) or S-1, irinotecan and oxaliplatin (S-IROX) demonstrated improved clinical benefits compared with nab-paclitaxel and gemcitabine. Evidence Rating Level: 1 (Excellent) The vast majority of patients with pancreatic cancer have metastatic disease at diagnosis, with a poor prognosis. The standard of […]
The post mFOLFIRINOX may have a limited role in pancreatic cancer in Phase II/III trial first appeared on 2 Minute Medicine.Source: 2 Minute Medicine